Sandoz pulls injectable methotrexate due to particulate matter

05/22/2013 | MedPage Today (free registration)

Sandoz recalled two lots of its methotrexate sodium USP, 25 mg/mL, 40 mL vial injectable drug, which is indicated for rheumatoid arthritis, severe psoriasis and neoplastic diseases. The drugmaker found particulate matter in vials of lots CL0996 and CJ4948 while performing a routine quality inspection. Parenteral injection of the recalled products "can lead to microembolisation in areas where the particles lodge," the FDA warned in a press release.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA